Rates of prostate cancer across Europe since 1980 are 'indicative of overdiagnosis,' say researchers in a study published by The BMJ.
Prostate cancer rates across Europe since 1980 are 'indicative of overdiagnosis,' say experts retrieved 4 September 2024 from https://medicalxpress.com/news/2024-09-prostate-cancer-europe-indicative-overdiagnosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.7 hours ago Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
WHO Europe laments declining rates of condom use among sexually active teens worldwideThe World Health Organization's office for Europe on Thursday decried a decline in condom use by adolescents in recent years, warning of risks of infection and unplanned pregnancies in countries from Canada to central Asia.
Read more »
Review suggests many men with early prostate cancer may not need lymph node removalFor years, the treatment of early-stage prostate cancers that haven't spread beyond the organ has often included the removal of nearby lymph nodes in the pelvis. It's done as a precaution and as a means of 'staging' the disease.
Read more »
Deep learning model rivals radiologists in detecting prostate cancer on MRIResearchers assess the power of a fully automated deep learning model to identify of clinically significant prostate cancer.
Read more »
Precision medicine enhances prostate cancer treatment with genetic profilingMen with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy.
Read more »
Precision therapy for metastatic prostate cancer offers improved survivalMen with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy. However, the effect depends on which mutations the patient's tumor carries.
Read more »
Olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancerThe anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a Phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.
Read more »